latest news releases from the newsroom
The Microbe Environment Connection - New book offers laymen's guide to microorganisms and environmental protection
LONG BEACH, Calif., Nov. 21, 2003 (PRIMEZONE) -- Microorganisms are the most numerous and important organisms on Earth, writes David M. Carlberg, Ph.D. They play a vital role in everything humans and other species do to survive, which makes them a crucial focus in environmental activism. In the new book, Biofilms and Dead Zones: The Microbe-Environment Connection: How Unseen Life Influences the World Around Us (now available through 1stBooks), Carlberg presents one of the first layman guides about the importance of microorganisms to the health of Earth's environment.
Landskroner Grieco Merriman, LLC
Landskroner - Grieco, Ltd. Notice of Filing Securities Class Action Against Friedman's, Inc., Victor M. Suglia, Bradley J. Stinn, Sterling Brinkley and Douglas Anderson -- FRM, FRDM
CLEVELAND, Nov. 21, 2003 (PRIMEZONE) -- Landskroner - Grieco, Ltd. announces that it filed a class action lawsuit against Friedman's, Inc., Victor M. Suglia, Bradley J. Stinn, Sterling Brinkley and Douglas Anderson. The class action lawsuit is pending in the United States District Court for the Northern District of Georgia. The lawsuit was filed on behalf of all persons who purchased or otherwise acquired the securities of Friedman's, Inc. ("Friedman's" or the "Company"), (NYSE:FRM and formerly Nasdaq:FRDM), between January 26, 2000 and November 17, 2003, inclusive, (the "Class Period").
Wolf Popper LLP
Wolf Popper LLP Updates the Status of Securities Fraud Class Action Against Biovail Corporation -- BVF
NEW YORK, Nov. 21, 2003 (PRIMEZONE) -- On November 14, 2003, Wolf Popper LLP, a firm specializing in securities class actions, filed a complaint against Biovail Corporation (NYSE:BVF) and certain of its senior officers alleging violations of the federal securities laws. The lawsuit was brought on behalf of all persons who purchased Biovail common stock on the open market during the period April 29, 2003 through November 10, 2003, inclusive. The complaint alleged, among other things, that Biovail concealed the adverse impact against its earnings resulting from (a) the termination of a marketing program for its main product following scrutiny by U.S. regulators; and (b) financial arrangements and transactions with other entities to avoid or minimize research and development expenses on Biovail's income statement. A copy of the complaint is available from the U.S. District Court for the Southern District of New York, and on Wolf Popper's website (www.wolfpopper.com).
Maxus Technology Inc.
Medinex Systems, Inc. Completes Exchange with Maxus Technology Inc.; Company Name & Symbol Change to Follow
SAN JOSE, Calif., Nov. 21, 2003 (PRIMEZONE) -- Medinex Systems, Inc. (OTCBB:MNXS) On November 14, 2003, Medinex Systems Inc. completed a stock exchange transaction with the stockholders of Maxus Technology Inc., or "Maxus". As a result of this transaction, Medinex continued to the business operations of Maxus, with management of Maxus assuming similar positions with Medinex. Medinex intends to change its name as soon as possible to better reflect the new business operations of the company. The common shares of the company will trade on the Nasdaq Over-the-counter Bulletin Board under the symbol "MNXS" until a new symbol can be obtained following the pending name change.
Now You Can See More Of Europe In Spring Thanks To Go-Today.Com!
BOTHELL, Wash., Nov. 21, 2003 (PRIMEZONE) -- Now thanks to Go-Today.com you can choose double the destinations, for a lower price! Combine 2 of your favorite cities in Europe and visit them on a vacation you thought you might never be able to afford! From fascinating culture, to decorative scenery, we offer it all! You must book soon though to avoid missing out!
The FDA's advisory panel recommends approval of RESTYLANE
STOCKHOLM, Sweden, Nov. 21, 2003 (PRIMEZONE) -- The FDA, Food and Drug Administration, the American regulatory authority, convened an advisory panel on Friday with some of the world's leading experts within plastic surgery. The panel recommended that the FDA approve RESTYLANE in the USA by 6 votes to 3 with certain conditions.
Harsco Corporation to Webcast December 8th Meeting With Analysts
HARRISBURG, Pa., Nov. 21, 2003 (PRIMEZONE) -- Harsco Corporation (NYSE:HSC) invites Harsco stockholders and the public to access a live Webcast of its presentations to investment analysts on Monday, December 8, 2003 beginning at approximately 8:30 am ET. Harsco senior executives, led by Chairman, President and CEO Derek C. Hathaway, will provide an update on Harsco's global businesses and markets. The meeting is expected to conclude at approximately 12:30 pm ET.